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Abstract Thrombospondin (TSP) 1 and TSP2 have been
implicated in the regulation of several processes during
tissue repair. Due to their matricellular nature, these
proteins are thought to modulate cell-matrix interactions
through a variety of mechanisms specific to the spatio-
temporal context of their expression. Most notably, TSP1
and TSP2 appear to play distinct, non-overlapping roles in
the healing of skin wounds. In contrast, both proteins have
been implicated as regulators of ischemia-induced angio-
genesis. Moreover, TSP2 has been shown to be a critical
regulator of angiogenesis in the foreign body response
(FBR). In this review, we discuss the role of TSPs in tissue
repair and examine the mechanistic data regarding the
ability of the thrombospondins to modulate cell-matrix




cGMP cyclic guanyl monophosphate
bFGF basic fibroblast growth factor
ECs endothelial cells
eNOS endothelial nitric oxide synthase
ECM extracellular matrix
FBR foreign body response
FBGCs foreign body giant cells
HUVECs human umbilical vein endothelial cells
IAP integrin associated protein
IL-1β interleukin 1β
HSPGs heparin sulfate proteoglycans
LAP latency associated protein
LRP1 low density lipoprotein related protein 1
LPA lysophosphatidic acid




SPARC secreted protein acidic and rich in cysteine
SMCs smooth muscle cells
sGC soluble guanylyl cyclases
SC subcutaneous
TSP thrombospondin
TSR thrombospondin type I repeat
tTG tissue transglutaminase 2
TGF-β1 transforming growth factor β1
TNF-α tumor necrosis factor α
UVB ultraviolet-B
VLDLR very low density lipoprotein receptor
VEGF vascular endothelial growth factor
WT wild type
Introduction
Thrombospondin (TSP) 1 and TSP2 are matricellular
proteins, and as such are released and/or secreted following
tissue injury and associate with the extracellular matrix
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DOI 10.1007/s12079-009-0077-z(ECM) to exert cellular effects (Reviewed in this issue). In
addition to its association with the ECM, TSP1 is a major
component of platelet α-granules and can also be found in
circulation while TSP2 is typically a product of fibroblasts.
Despite their high sequence homology, these molecules
have largely non-overlapping functions, as exemplified by
their unique cellular distribution and temporal expression,
as well as by the distinct phenotypes of the respective
knockout animals (Crawford et al. 1998; Kyriakides et al.
1998a; Lawler et al. 1998). TSP1 was the first identified
endogenous inhibitor of angiogenesis, and its role as a
critical regulator of tumor progression via modulation of
angiogenesis is well established (Reviewed in (Kazerounian
et al. 2008; Zhang and Lawler 2007)). Moreover, a frag-
ment of TSP1 (ABT-510) is in phase II clinical trials as an
anti-angiogenic cancer therapy (Baker et al. 2008). Simi-
larly, TSP2 exerts anti-angiogenic effects and can influence
processes including inflammation and tissue remodeling
(Kyriakides and Bornstein 2003). Although TSP1 and
TSP2 are dispensable for developmental angiogenesis, they
are critical for proper tissue repair, as will be discussed in
this review.
Damage to tissue is resolved through a series of over-
lapping processes that lead to variable outcomes including
resolution, fibrosis, or scarring. Although the resolution of
tissue repair is a diverse process that depends on the extent
and site of damage, TSP1 and TSP2 are implicated in a
number of tissue-injury settings. Overall, TSP1 and TSP2
are critical for proper neovascularization and are typically
associated with proper ECM organization, but the molec-
ular mechanisms regulating these processes have not been
elucidated. TSP1 and TSP2 are proposed to act through
direct interactions with cell receptors and/or indirectly by
modulating the composition of the extracellular milieu.
Binding of TSP1 and TSP2 to cell-surface receptors
involves integrins, integrin associated protein (IAP)/CD47,
CD36, heparin sulfate proteoglycans, low density lipopro-
tein related protein 1 (LRP1), and very low density lipo-
protein receptor (VLDLR). These direct interactions lead to
alterations in cell proliferation and survival, extracellular
matrix remodeling, and blockade of nitric oxide (NO)
signaling. Indirect interactions mediated by TSPs include
the alteration of levels or bioavailability of effector
molecules including basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF) (Greenaway
et al. 2007; Gupta et al. 1999; Taraboletti et al. 1997)a s
well as matrix metalloproteinase (MMP)-2 and MMP-9,
which can alter ECM structure and cell function. In
addition, TSP1 can activate transforming growth factor
(TGF)-β1. Historically, the efforts to elucidate these
mechanisms have focused on TSP1, and it was assumed
that TSP2 shared these functions due to its high sequence
and structural homology with TSP1. However, it is now
appreciated that TSP1 and TSP2 differ in their mechanisms
of action (Fig. 1). For example, TSP2 does not activate
TGF-β1. In addition, TSP1 binds CD47 with higher affinity
than TSP2 and is thought to be more efficient in inhibiting
NO signaling (Isenberg et al. 2009). Moreover, unlike
TSP2, TSP1 cannot inhibit angiogenesis in a three-
dimensional assay (Krady et al. 2008). However, there are
some similarities between the proposed mechanisms of
action of TSP1 and TSP2. Specifically, in vitro studies have
shown that both TSP1 and TSP2 are capable of binding
MMP-2 or MMP-9 and enhancing their cellular uptake and
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Fig. 1 Schematic diagram of significant TSP1 and TSP2 interactions
in tissue repair. Interactions are shown based on their importance for
each molecule independently or those verified to be shared by both
TSP1 and TSP2. Molecules listed in bold are discussed in the review.
All molecules are spatially oriented near the known and putative TSP
domains they interact with. NH2, amino terminus includes heparin
binding site; PC, pro-collagen homology region; I, type I properdin-
like repeats (TSR); II, type II EGF homology repeats; III, type III
repeats include calcium binding sites; COOH, carboxy terminus
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2001; Yang et al. 2000).
In this review we discuss the current understanding of
the roles of TSP1 and TSP2 in tissue repair (summarized in
Table 1). We focus primarily on their influences in wound
healing, ischemia, and the foreign body response but also
review several other models of repair-associated processes.
For each model, we also discuss the pertinent mechanistic
data regarding their function.
Wound healing
Expression of TSPs during dermal wound repair
Healing of cutaneous wounds requires sequential and
overlapping phases of inflammation, cell proliferation/
migration, and tissue remodeling (Singer and Clark 1999).
Many bioactive molecules such as cytokines, growth
factors, and matricellular proteins including TSP1, TSP2,
osteopontin, and secreted protein acidic and rich in cysteine
(SPARC) play critical roles in this process. In dermal
wound healing, the spatial and temporal expression of
TSP1 and TSP2 are distinct (Agah et al. 2002; Kyriakides
et al. 1999b). TSP1 expression is typically low in uninjured
skin, is induced acutely following wounding (d 1-3), and
returns to basal levels as inflammation resolves. TSP1 is
found primarily associated with the ECM and in thrombi.
Degranulation of the α-granules of platelets is the major
contributor of TSP1 post injury, but in situ hybridization
and immunohistochemistry have also revealed wound bed
smooth muscle cells, macrophages and endothelial cells as
sources of TSP1 (DiPietro et al. 1996; Raugi et al. 1987).
Specifically, in human excisional wounds TSP1 was
distributed at the lateral and deep wound margins between
2 and 7 d post wounding, and diminished by d 14 (Raugi et
al. 1987). In the same study, vessels adjacent to granulation
tissue in d 7 and d 14 wounds displayed greater TSP1
immunoreactivity relative to that in distal vessels. In a
mouse study, mRNA for TSP1 was undetectable in normal
skin and increased at d 1 following full-thickness wound
and was undetectable again at d 10 (DiPietro et al. 1996).
This study concluded that macrophage-like cells repre-
sented the primary source of TSP1 in wounds.
Table 1 Summary of TSP-associated tissue repair phenotypes
Model TSP1 KO TSP2 KO TSP1/TSP2 Double KO
Wound healing Prolonged inflammation Enhanced angiogenesis Prolonged inflammation
Delayed wound closure, delayed
scab loss and reepithelialization
Accelerated wound closure Delayed wound closure, delayed scab
loss and reepithelialization
Normal angiogenesis Irregular ECM assembly Normal angiogenesis
Altered granulation tissue
morphology
Increased MMP-2 and MMP-9 Altered granulation tissue morphology
Decreased MCP-1 Increased soluble VEGF Decreased MCP-1
Decreased TGF-β (total and active) Decreased TGF-β (total and active)
Hindlimb ischemia Enhanced angiogenesis Enhanced angiogenesis Enhanced angiogenesis
Enhanced blood flow recovery Enhanced blood flow recovery Increased platelet-derived SDF-1
Involves NO signaling Increased baseline arteriogenesis
Macrophage-dependent Increased MMP-9
Skin Flap Increased survival Normal Normal
Involves CD47 and NO signaling
Polyninyl alcohol
sponge Implantation
Not determined Enhanced angiogenesis Not determined
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The role of thrombospondins in wound healing, ischemia, and the foreign body reaction 217TSP2 is present in normal skin at very low levels in an
ECM-associated pattern (Agah et al. 2004; Kyriakides et
al. 1998b). Deposition of TSP2 is increased in dermal
wounds as early as d 3 and reaches peak levels at d 10.
Expression of TSP2 in platelets and endothelial cells (ECs)
is below detection levels, and the major contributors to
wound TSP2 are fibroblasts and smooth muscle cells (Agah
et al. 2004). Immunohistochemistry revealed deposition of
TSP2 in granulation tissue ECM and in fibroblast-like cells
following full thickness wounds (Kyriakides et al. 1999b).
The spatiotemporal expression of TSP1 and TSP2 impli-
cates their unique functions in wound healing. This
distinction is underscored by the fact that the wound
site is dramatically altered between the peaks in expression
of the two molecules. TSP1 is induced early in wound
healing, concomitant with thrombus formation, edema
and inflammation. TSP2 expression occurs after resolution
of the inflammatory phase and during granulation tissue
remodeling.
Thrombospondin 1 and wound healing
Wound healing studies in TSP1-null mice indicated delayed
repair, characterized by loosely compacted and disorga-
nized granulation tissue (Agah et al. 2002). Macrophage
influx and blood vessel density following wounding were
reduced compared to WT wounds (Agah et al. 2002). In the
same study, TSP1-null wounds were found to contain
decreased levels of both total and active TGF-β1. TSP1 is
believed to be a major in vivo activator of TGF-β1 as
TSP1-null mice revealed suppressed active TGF-β1 levels,
which were restored to normal levels by the addition of
the TSP1-specific peptide activating sequence (KRFK)
(Crawford et al. 1998). The importance of TSP1-mediated
TGF-β1 activation is supported by the observation that
collagen gel contraction, an in vitro model for wound
contraction, was enhanced by addition of TSP1, with a
concordant increase in active TGF-β1, and reduced by
antibody-mediated functional knockdown of either TSP1 or
TGF-β1 (Sakai et al. 2003).
Wound healing in TSP1/TSP2 double-null mice pheno-
copies that in TSP1-null animals, indicating that the initial
loss of TSP1 dictates the course for wound healing (Agah et
al. 2002). Similarly, transient knockdown of TSP1 using an
antisense oligomer strategy led to a decreased rate of re-
epithelization and delayed dermal reorganization, (DiPietro
et al. 1996). It is important to note that this oligomer
strategy decreased wound macrophage TSP1 production
(55–66% reduction) but did not affect previously synthe-
sized TSP1 (platelets, epidermal-dermal junction) (DiPietro
et al. 1996).
Interestingly, excisional wounds in transgenic mice with
TSP1 expression controlled by a keratin promoter displayed
delayed healing with decreased granulation tissue formation
and wound neovascularization (Streit et al. 2000). Uninjured
skin in transgenic mice had no obvious structural changes
and had normal basal vessel density, architecture, and
permeability (Streit et al. 2000). Delayed healing was
attributed to an increase in apoptosis in the wound bed,
involving mostly fibroblasts. In the same study it was
shown that addition of TSP1 decreased the migration of
fibroblast and ECs in vitro. Moreover, there was reduced
EC proliferation in the presence of TSP1 in vitro. It should
be noted that the quantity and duration of TSP1 expression
in these mice exceeds that of WT mice, which is limited to
the first 5 d post-injury.
Thrombospondin 2 influences wound healing
Full thickness wounds in TSP2-null animals healed at an
accelerated rate compared to WTand displayed alterations in
the remodeling phase of healing (Kyriakides et al. 1999b).
Complete reepithelization of full thickness excisional
wounds occurred earlier than WT, and the epithelial layer
displayed increased thickness. Granulation tissue at the
wound site was disorganized with a basket weave mor-
phology of collagen fibers and altered distribution of
fibronectin. In addition, TSP2-null wounds were found to
have increased cellular content and vascular density, which is
consistent with the anti-angiogenic function of TSP2.
Subsequent studies of TSP2-null wounds revealed increased
MMP-2 and MMP-9 in the ECM, as well as increased
soluble vascular endothelial growth factor (VEGF) in wound
tissue (Krady et al. 2008; MacLauchlan et al. 2009). In vitro
studies have shown that TSP1 can directly bind and
sequester VEGF, serving to decrease VEGF receptor-
mediated signaling (Greenaway et al. 2007). Despite the in
vitro observation that TSP1 and TSP2 can induce apoptosis
and prevent proliferation, neither process was influenced by
the lack of TSP2 during wound healing. Specifically, detec-
tion of proliferating and apoptotic cells in wounds revealed
similar levels between TSP2-null and WT mice. Although
myofibroblast content was equivalent between TSP2-null
and WTwound beds, TSP2-null wound fibroblasts displayed
altered morphology in stressed collagen gels and reduced
contraction of relaxed collagen gels, indicating an inherent
deficit in contractility (MacLauchlan et al. 2009). Taken
together, these findings suggest that TSP2 influences
fibroblast-ECM interactions, possibly through MMP-
mediated ECM remodeling.
The observation that TSP2 expression increases with age
and contributes to the delayed healing of aged mice provides
further support for its critical role in wound healing (Agah et
al. 2004). Interestingly, the same study demonstrated that
peak TSP2 expression shifted to d 14 in aged mice, as was
the increase in MMP-2 in aged TSP2-null wounds.
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and arteriogenesis
Hypoxia can trigger inflammation-driven angiogenesis in
ordertoimproveblood-flowtoischemictissues.Thefunction
of TSPs has been investigated in two ischemic models,
namely hindlimb ischemia and random myocutaneous flap.
Similar to wound healing, hindlimb ischemia in mice,
accomplished by ligation or excision of the femoral artery,
has been used as a robust model of physiologic angiogenesis
and arteriogenesis (Heil et al. 2006). Following excision,
there is a resulting drop in pressure in the distal vasculature
and a pressure gradient causes increased flow through pre-
existing collaterals (Heil and Schaper 2004). A number of
responses are then elicited, including activation of the
endothelium, up-regulation of adhesion molecules, and
inflammatory factors. These responses are accompanied by
invasion of circulating monocytes that contribute to the
digestion of the ECM. Smooth muscle cells, in turn, migrate
and proliferate causing enlargement of blood vessels and
eventually allow for restoration of fluid shear and wall
stresses to normal levels. A number of conditions determine
the overall efficacy of the growth of collateral vessels. These
include the existence of an arterial network that connects the
microcirculation, the activation of the endothelium by
elevated fluid shear stress, the invasion of bone marrow-
derived cells, and the proliferation of ECs and smooth
muscle cells (SMCs). In addition, this model causes regional
hypoxia and mismatch between oxygen supply and demand
in skeletal myocytes in the distal limb (Heil and Schaper
2004; Heil and Schaper 2005). Once a stable, collateral
circulation is established, the improvement in distal blood
flow and shear stress triggers an increase in capillary
angiogenesis, thus increasing capillary to fiber ratios and
oxygen delivery to the dependent portions of the lower
limb. Therefore, proportionally regulated arteriogenesis and
angiogenesis are necessary to improve nutritive blood flow
to tissue and promote functional limb salvage.
TSP2 expression in ischemic muscle was robust in
ischemic muscles at 1 wk post-injury, followed by a drop in
expression between 1 and 3 wks, and a subsequent increase
at 4 wks (Krady et al. 2008). Immunohistochemical
analysis indicated an extensive association of TSP2 with
muscle fibers and interstitial fibroblasts early in the recovery
process. At 4 wks, TSP2 expression was also observed in
close association with blood vessels. TSP2-null mice were
shown to have enhanced arteriogenesis, angiogenesis and
recovery of blood flow following ischemia in comparison to
control mice. Specifically, TSP2-null mice were shown to
have an increased number of vessels and capillary-to-fiber
ratios throughout the recovery period. Remarkably, com-
pared with WT mice, baseline arteriogenesis was greater in
TSP2-null mice as shown by quantitative angiography.
Moreover, the number of collaterals was found to be higher
in TSP2-null mice, indicating the presence of an enhanced
arterial network. Increased baseline arteriogenesis in TSP2-
nulllimbs suggestedthattheabilitytouseexistingcollaterals
to supply blood flow to the distal limb is enhanced in
these mice. Contraction-stimulated hyperemia in the gas-
trocnemius muscle in WT and TSP2-null mice at baseline,
induced by electrical stimulation of the adductor muscle
groups, was greater in TSP2-null mice. Taken together, these
findings suggest that TSP2 functions as a critical regulator of
the vasodilation necessary for the gradual return of blood
flow to normal levels. These observations are the first to link
any TSP with the process of arteriogenesis. In a separate
study using the same model, it was shown that TSP2-null
mice display normalrecoveryofbloodflowinthe first 72hrs
following ischemia (Isenberg et al. 2009). This is not
surprising,sinceTSP2isnotexpressedduringthistimeframe.
The spatiotemporal expression of TSP1 mRNA in the
hindlimb ischemia model has recently been described
(Brechot et al. 2008). Similar to wound healing, in situ
hybridization revealed high levels of TSP1 expression in
macrophages at d 4 and d 6 post-injury. At d 16 and d 21
TSP1 expression was diminished and was predominantly
associated with EC. In the same study, TSP1-null mice
were protected from ischemia-induced necrosis due to
increases in angiogenesis and muscle fiber regeneration.
However, in this study, C57Bl6 WT mice displayed
excessive necrosis following excision of the femoral artery,
which is highly unusual for this strain. Interestingly, the
protective effect of TSP1 deficiency was reversed following
macrophage depletion in TSP1-null mice. Moreover, TSP1-
null macrophages isolated from d 4 ischemic muscles were
found to be less pro-inflammatory. Thus, in this model it
appears that macrophage-derived TSP1 plays a critical role
in inflammation-induced angiogenesis.
Analysis of the ischemic response in double TSP1/TSP2-
null mice showed an improved phenotype consistent with
that observed in the single TSP1-null and TSP2-null mice
and was attributed to increased angiogenesis due to
increased MMPs and platelet production (Kopp et al.
2006). In the same study, bone marrow transplantation
experiments showed that the improved phenotype could be
transferred to wild type mice that received double-null
marrow. This observation prompted the investigators to
hypothesize that TSPs derived from circulating cells could
regulate the ischemic response. Specifically, it was pro-
posed that platelet-derived TSPs regulate ischemia-induced
angiogenesis. It should be noted that platelets do not
contain TSP2 and TSP2-null platelets have an inherent
aggregation defect (Kyriakides et al. 2003). Moreover, a
recent report showed that in the presence of exogenous
NO TSP1-null platelets fail to aggregate in response to
thrombin (Isenberg et al. 2007c). Thus, reintroduction of
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results that are more relevant in the context of suboptimal
platelet activation.
The Foreign Body Response (FBR)
In many ways the FBR is similar to wound healing in that
both initiate with tissue injury and trigger inflammatory
responses. However, whereas inflammation gives way to
healing in normal repair, implantation of a biomaterial or
other persistent foreign body presents prolonged inflamma-
tory signals that elicit fibrosis, formation of foreign body
giant cells (FBGCs) and almost complete regression of
vascular structures, leading to the formation of mostly
avascular collagenous capsules (Anderson et al. 2008).
Experimentally, solid biomaterials implanted SC undergo
encapsulation in the time span of 4 wks. Alternatively,
implantation of porous sponges (polyvinyl alcohol, PVA)
induces sponge granuloma formation within 3 wks, which
allows evaluation of angiogenesis and ECM remodeling
(Reviewed in (Kyriakides and Bornstein 2003)). Thus far,
only the role of TSP2 in the FBR has been studied. TSP1
might also influence the FBR, particularly due to its anti-
angiogenic function and its role in wound inflammation.
In the context of the FBR, TSP2 expression was high
within the foreign body capsule, at the implant interface,
and was associated with fibroblasts proximal to the capsule
(Kyriakides et al. 1999a; Kyriakides et al. 2001b). Silicone
(PDMS) disks implanted subcutaneously (SC) into TSP2-
null animals induced the formation of capsules that were
thicker than WT, irregular in organization, and contained an
increased number of blood vessels (Kyriakides et al.
1999a). The collagenous capsule surrounding the implant
lacked organization and was associated with decreased
collagen packing and a loss of the parallel arrangement
of collagen fibers (Kyriakides et al. 1999a). This was the
first demonstration of the FBR with sustained capsule
vascularization. Similar to solid implants, PVA sponges
implanted in TSP2-null animals induced increased angio-
genesis and less organized fibrosis than WT (Kyriakides et
al. 2001b). Moreover, solid implants and PVA sponges
treated with a gene-activated matrix containing TSP2
antisense plasmid and implanted in WT mice induced
thicker, irregular, and well-vascularized capsules that
displayed altered fibronectin distribution and misaligned
collagen fibers (Kyriakides et al. 2001a). These changes
were associated with increased MMP-2; no significant
change in active TGF-β1 was detected (Kyriakides et al.
2001b). In the same study restoration of TSP2 by cDNA
delivery reversed the TSP2-null phenotype. Consistent with
the role of matricellular proteins in tissue repair, SPARC-
TSP2 double-null mice were shown to have increased
fibrovascular invasion into PVA sponges, associated with
increased levels of MMP-2 (Puolakkainen et al. 2005).
A recent study involving implantation of PVA sponges
in the mouse brain cortex confirmed the significance of
TSP2 in regulating fibrotic and angiogenic responses, but
underscores the tissue specificity of the FBR as neuro-
inflammation and permeability of the blood brain barrier
were severely compromised in TSP2-null animals (Tian
and Kyriakides 2009). Previous studies using TSP2-null
animals did not demonstrate altered macrophage or inflam-
matory cell recruitment to the biomaterial in the FBR. As
in the SC space, PVA sponges in the TSP2-null brain
displayed increased levels of MMP-2 and MMP-9.
Thrombospondins in models of skin inflammation
and UV light damage
Adult skin microvasculature is mostly quiescent, except when
angiogenesis is stimulated by damage, pathologic conditions,
andduringgrowthofthe hairfollicle(Detmar 2000). The role
of TSPs in normal skin angiogenesis is well appreciated
(Detmar 2000) and is discussed here briefly, focusing on
damage models including photodamage and inflammation.
Hairgrowth requires coordinated induction and regression
of vessels proximal to the follicle during the anagen and
catagen phases of the hair life cycle, respectively (Yano et al.
2003). TSP1 expression was induced during the involution
phase, which is characterized by vascular regression and
follicle growth. Involution in TSP1-null mice was signifi-
cantly prolonged and characterized by increased vascularity,
resulting in a longer hair growth phase and longer follicles
(Yano et al. 2003). Moreover, transgenic overexpression of
TSP1 resulted in the opposite phenotype, with decreased
vascularization of the follicle resulting in shorter hair
follicles (Yano et al. 2003). These changes are consistent
with the requirement for vascularization of the follicle for
proper growth and the well documented anti-angiogenic
function of TSP1 (Detmar 2000).
Ultraviolet-B (UVB) irradiation induces dermal damage
that is associated with changes in epithelial cells, leading to
ECM degradation, wrinkle formation, and vascular changes,
including dilation and hyperpermeability (Yano et al. 2002).
Transgenic TSP1 mice were protected against UVB damage,
and this protection was attributed to blocked induction of
vascular responses, as measured by decreased vasculariza-
tion, decreased EC proliferation, and induction of EC
apoptosis (Yano et al. 2002). Furthermore, these mice were
protected against wrinkle formation (Yano et al. 2002). In
WT mice, TSP1 was depressed while VEGF and transient
neovascularization were induced by a single dose of UVB
irradiation (Yano et al. 2004). This hypothesis is supported
by UVB-mediated induction of angiogenesis and con-
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et al. 2005). The role of TSP2 has not been explored in these
models.
There is a clear role for angiogenesis in the development
of inflammatory diseases, including chronic skin inflam-
mation (Jackson et al. 1997). TSP1 and TSP2, as well as
the receptor CD36, are induced by inflammatory stimuli
(Lange-Asschenfeldt et al. 2002; Velasco et al. 2009). TSP1
was present in the basement membrane of the dermal-
epidermal junction in non-inflamed skin and was detected
in blood vessels and more strongly in the epidermis
following induction of inflammation (Velasco et al. 2009).
Inflammation-induced TSP2 was associated primarily with
dermal fibroblasts (Lange-Asschenfeldt et al. 2002). Lack
of either TSP1 or TSP2 resulted in increased inflammation-
induced vessel density, edema, and inflammatory infil-
tration leading to prolonged and exacerbated reactions
(Lange-Asschenfeldt et al. 2002; Velasco et al. 2009).
Interestingly, TSP2-null mice displayed increased rolling of
leukocytes in non-inflamed skin, which might enhance
leukocyte trafficking and influx into tissues (Lange-
Asschenfeldt et al. 2002). Moreover, inflammatory stimuli
induced interleukin (IL) -1β, macrophage inflammatory
protein 2 (MIP2), and tumor necrosis factor (TNF) -α to a
greater extent in TSP1-null animals, contributing to the pro-
inflammatory state (Velasco et al. 2009). Although this
study did not explore the role of MMPs in the context of
this model, it is interesting to note that IL-1β is activated by
MMP-mediated cleavage (Schonbeck et al. 1998)a n d
MMPs would be expected to be high in the TSP1-null
environment. Consistent with the observations outlined
above, over-expression of TSP1 in transgenic mice was asso-
ciated with protection against edema formation due to
decreased vessel density and permeability (Velasco et al.
2009).
Thrombospondin in other healing models
The roles of TSPs in other healing models are quickly
becoming appreciated. In the context of the anti-Thy1-
induced kidney injury, TSP1 was associated with progres-
sion to kidney fibrosis by activation of TGF-β1 (Reviewed
in (Basile 1999; Hugo 2003)). In various eye injury models
TSPs have been implicated in a variety of roles (Reviewed
in (Hiscott et al. 2006)). The eye represents a unique site for
wound healing because it has avascular and immuno-
privileged regions. TSP1 is induced during corneal ischemia
(Suzuma et al. 1999) and TSP1-null mice were protected
against vessel obliteration following oxygen-induced reti-
nopathy, due to increased EC density and decreased EC
apoptosis (Wang et al. 2003). Alternatively, exogenous
TSP1 and antibody-mediated knockdown of TSP1 demon-
strated a positive role for TSP1 on re-epithelization of
corneal scratch wounds (Uno et al. 2004). The role of TSP2
in these models is not well studied, but is strongly induced
concomitant with VEGF during healing of corneal alkali
burns (Yan et al. 2007). Moreover, in a model of oxygen
induced retinal ischemia in CYP1B1-null mice TSP2 expres-
sion was induced by reactive oxygen species (ROS) and the
increase was sensitive to antioxidants (Tang et al. 2009).
Consistent with a role of ROS in inducing TSP2 expression,
constitutive active Rac V
12 driven ROS production induced
TSP2 in human aortic endothelial cells (Lopes et al. 2003).
As discussed above, there is a critical role of TSPs in
ischemia-induced angiogenesis. Consistent with this sug-
gestion, it was shown that cerebral ischemia generated by
stroke induced TSP1 expression acutely (1 to 72 hrs post
insult) and TSP2 expression 2 wks following injury (Lin et
al. 2003). In this model, the pattern of TSP1 and TSP2
expression correlated temporally with just prior to and just
after the angiogenic component of ischemia, respectively
(Lin et al. 2003). However, it is unclear whether TSP1 or
TSP2 are required for proper healing following stroke. Each
of these healing models represents exciting avenues for
future research.
Mechanism of action of TSPs
As discussed above, multiple mechanisms have been pro-
posed to explain the roles of TSP1 and TSP2 in tissue repair,
and especially during angiogenesis (Table 1). Generally,
TSPs are believed to induce EC apoptosis and prevent EC
proliferation, affect cell migration, and block NO signaling.
In this section we evaluate the in vitro data supporting each
of these mechanisms and their relevance in vivo.
TSP1, TSP2, and MMPs
MMPs play critical roles in wound healing, in particular
due to their established pro-angiogenic function (Page-
McCaw et al. 2007; Yang et al. 2000). The gelatinases
MMP-2 and MMP-9 complex with either TSP1 or TSP2
through their TSP type I (TSR) repeats (Bein and Simons
2000). This complex is recycled by its interaction with the
scavenger receptor, LRP1 (Emonard et al. 2004; Hahn-
Dantona et al. 2001; Yang et al. 2001). TSP1 and TSP2 are
not cleaved by either MMP-2 or MMP-9 in this complex
(Bein and Simons 2000; Yang et al. 2000). An inverse
correlation between the levels of TSP2 and MMPs was
observed in vivo in dermal wound healing, hindlimb
ischemia, and the FBR (Krady et al. 2008; Kyriakides et
al. 2001b; MacLauchlan et al. 2009; Tian and Kyriakides
2009). More importantly, in situ zymographic analysis
revealed increased gelatinase activity in TSP2- null cells
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model, MMP-2, MMP-9, or both were influenced by the
deficiency of TSP2. Presumably, this is a reflection of the
cellular variability and resulting spatiotemporal expression
of these enzymes in the different models. For example, both
MMP-2 and MMP-9 were increased in TSP2-null dermal
wounds (MacLauchlan et al. 2009) whereas in hindlimb
ischemia only the latter was increased (Krady et al. 2008).
MMPs have multiple roles in tissue repair including their
ability to remodel granulation tissue and modulate the
bioactivity and levels of molecules such as growth factors
and cytokines. For example, the high levels of MMPs in
TSP2-null dermal wounds were associated with increased
amounts of soluble VEGF. This observation was consistent
with previous studies demonstrating that MMPs are capable
of releasing matrix-bound VEGF (Belotti et al. 2003;
Bergers et al. 2000; Lee et al. 2005). Interestingly, in
TSP2-null dermal wounds the increase in MMPs was also
shown to influence the levels of tissue transglutaminase 2
(tTG) (Agah et al. 2005). tTG plays critical roles in the
stabilization of ECM by the introduction of γ-glutamyl-ε-
amino lysyl isopeptide cross-links into collagen, fibro-
nectin, and other matrix proteins (Lorand and Graham
2003). Thus, by modulating the levels of MMP-2 and/or
MMP-9 TSP2 can indirectly influence the stability and
integrity of the ECM as well as the levels of at least one
growth factor. Moreover, a recent study has implicated MMP-
9 in collagen fibrillogenesis during dermal wound healing
(Kyriakides et al. 2009). Thus, the increased levels of MMPs
in TSP2-null wounds could also influence ECM assembly.
TSPs and TGF-β1 activation
TSP1 can activate TGF-β1, but activation requires both a
TGF-β1 binding site (GGWSHW) and an activation site
(KRFK); TSP2 lacks the activation site (Schultz-Cherry et al.
1995) and TSP2 deficiency has not been associated with
changes in TGF-β1 activation (Kyriakides et al. 2001a).
Active TGF-β1 levels were decreased in the TSP1-null
animals (Crawford et al. 1998), as expected based on the
ability of TSP1 to activate latent TGF-β1 (Schultz-Cherry
et al. 1995; Yee et al. 2004). The biochemical activation
pathway of TGF-β1 is well described and can be achieved
by both proteolytic and non-proteolytic mechanisms (Jenkins
2008)( A n n e se ta l .2003). Active TGF-β1 is secreted in
the latent form as a dimer with its proprotein pro-TGF-β1
(referred to as the latency associated protein (LAP)) (Jenkins
2008). The interaction of TSP1 with TGF-β1 releases the
active TGF-β1 molecule from LAP (Annes et al. 2003). The
interactions between TSP1 and TGF-β1 are well described
(Reviewed in (Murphy-Ullrich and Poczatek 2000)) and
include regions of the TSR repeats (Schultz-Cherry et al.
1994), which interact with the active TGF-β1 (WSXW,
(Young and Murphy-Ullrich 2004)) and LAP (KRFK and
LSKL sequences (Crawford et al. 1998; Ribeiro et al. 1999;
Schultz-Cherry et al. 1995)) to disrupt the complex.
TSPs and CD36 interactions
A mechanism for the anti-angiogenic effect of TSP1 was
shown to involve the interaction of the type I repeats of TSP1
with the scavenger receptor CD36 on ECs (Dawson et al.
1997). Subsequently, a study determined the downstream
events that included activation of p59fyn, leading to
activation of p38MAPK, caspase 3-like proteases, and
induction of EC apoptosis (Jimenez et al. 2000). In the
same study, in vivo evidence for the involvement of this
mechanism in limiting angiogenesis was provided in a tumor
model. However, the importance of these mechanisms in the
regulation of physiological angiogenesis in wound healing or
ischemia has not been established. In fact, in ischemia
models it appears that the primary receptor for TSP1 in
vascular cells is CD47 and not CD36 (Isenberg et al. 2008b).
It is also unclear whether TSP2 can induce the activation of
this cascade, even though binding of TSP2 to CD36 on EC
has been reported (Simantov et al. 2005). In addition, a
recent report has shown that HUVEC, which express low
levels of CD36, remained insensitive to exogenous TSP2
even when transfected with a CD36 cDNA (Oganesian et al.
2008). Thus, the significance of TSP2-CD36 interaction in
injury-induced angiogenesis is unclear.
TSPs and blockade of NO signaling
A major canonical pro-angiogenic target of nitric oxide (NO)
is the activation of soluble guanylyl cyclases (sGC), leading
to increased intracellular pools of the second messenger
cGMP (Hoefer et al. 2006). Recently, TSP1 was demon-
strated to block nitric oxide (NO) mediated accumulation of
cGMP, revealing a new mechanism to blockade angio-
genesis (Reviewed in (Isenberg et al. 2008a)). At low,
physiologic levels of TSP1, this interaction was mediated by
the cell surface receptors CD47/integrin associated protein
(IAP) through undefined downstream mediators (Isenberg et
al. 2006a). At nanomolar concentrations, TSP1 was shown
to interact with the scavenger receptor CD36 and synergize
with CD47 to achieve this effect (Isenberg et al. 2006b;
Isenberg et al. 2005). Because exogenous myristic acid can
activate eNOS through CD36 (Zhu and Smart 2005) and
TSP1 peptides corresponding to the CD36 binding site
inhibit CD36 mediated myristic acid uptake (Isenberg et al.
2008a), it has been implied that TSP1 might inhibit eNOS
activity. Specifically, decreased intracellular myristic acid
might depress eNOS palmitoylation to achieve altered
activity (Isenberg et al. 2007a). However, there is no direct
evidence demonstrating that TSP1 decreases eNOS activity
222 T.R. Kyriakides, S. MacLauchlanand the importance of this proposed activity has not been
verified in vivo. The role of TSP2 in blocking NO signaling
is less well studied. However, TSP2 was recently described
to have lower affinity for CD47, and to be less active in
blocking NO-mediated cell adhesion (Isenberg et al. 2009).
This study also implied that TSP2 could decrease cGMP
accumulation in TSP1-null ECs by using a morpholino
knockdown strategy (Isenberg et al. 2009), but failed to
demonstrate a reduction in TSP2 protein levels. A second
possible TSP-mediated anti-angiogenic mechanism involves
the well-documented ability of TSP1 to inhibit NO signaling
in EC and SMC (Reviewed in (Isenberg et al. 2008a)).
According to several studies, TSP1 is an antagonist of NO/
cGMP signaling in ECs and has a biphasic effect on NO
production that is dependent on concentration (Isenberg et
al. 2005). Specifically, at physiological concentrations TSP1
acts via its receptor CD47 to limit sGC activation. In
addition, at supraphysiological concentrations, TSP1 can be
inhibitory via CD36, but CD47 is necessary for this effect.
Via these interactions, TSP1 acts as a potent inhibitor of
NO-stimulated EC proliferation, adhesion, and migration. A
series of in vivo studies utilizing genetic and biochemical
approaches have established the importance of the TSP1-
CD47 interaction in regulating NO signaling in vivo in the
context of ischemic injury. Specifically, TSP1-null mice
displayed enhanced tissue survival in a random myocuta-
neous flap model for ischemic injury due to increased
NO-mediated vasodilation (Isenberg et al. 2007b).
Conclusion
Since the discovery of TSP1 and TSP2, many studies have
focused on elucidating their functional significance and
mechanism of action. Generation of TSP1-null and TSP2-
null mice revealed that both proteins are dispensable in
embryonic development and do not play critical roles in
homeostatic processes. However, both TSP-null mouse
strains display abnormal responses to injury and the
resultant phenotypes have provided clues to their mecha-
nisms of action. Based on such studies, we suggest that
TSP1 has a critical role in the inflammatory phase of tissue
repair and antagonizes NO signaling in ischemia. More-
over, loss of TSP1 is associated with reduced activation of
TGF-β1 in dermal wound healing. TSP2 on the other hand,
is primarily involved in tissue remodeling via the modula-
tion of the levels of MMP-2 and MMP-9. Despite the
documented direct negative effects of TSP1 and TSP2 on
EC survival and/or growth in vitro, it not clear whether
such mechanisms are involved in tissue repair. More
detailed analysis of proliferation and apoptosis during
tissue repair is needed to clarify this issue. In addition,
studies utilizing tissue-specific deletions of TSP1 and/or
TSP2, as well as the generation of knock-in mice with
mutant forms of these proteins, should provide additional
clues to their precise mechanisms of action.
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